IN2014DN06808A - - Google Patents

Info

Publication number
IN2014DN06808A
IN2014DN06808A IN6808DEN2014A IN2014DN06808A IN 2014DN06808 A IN2014DN06808 A IN 2014DN06808A IN 6808DEN2014 A IN6808DEN2014 A IN 6808DEN2014A IN 2014DN06808 A IN2014DN06808 A IN 2014DN06808A
Authority
IN
India
Prior art keywords
conditions
hydrocortisone
depression
benefit
treatment
Prior art date
Application number
Inventor
Hiep Huatan
Richard Ross
Martin Whitaker
Original Assignee
Diurnal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd filed Critical Diurnal Ltd
Publication of IN2014DN06808A publication Critical patent/IN2014DN06808A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Abstract

The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone in particular conditions such as adrenal insufficiency inflammatory conditions and depression.
IN6808DEN2014 2012-02-13 2013-02-12 IN2014DN06808A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1202433.7A GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release
US201261599704P 2012-02-16 2012-02-16
US201261600958P 2012-02-20 2012-02-20
PCT/GB2013/050311 WO2013121184A1 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation

Publications (1)

Publication Number Publication Date
IN2014DN06808A true IN2014DN06808A (en) 2015-05-22

Family

ID=45930017

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6808DEN2014 IN2014DN06808A (en) 2012-02-13 2013-02-12

Country Status (28)

Country Link
US (2) US9750704B2 (en)
EP (1) EP2814469B1 (en)
JP (1) JP6293678B2 (en)
KR (1) KR102023559B1 (en)
CN (2) CN110141557A (en)
AU (1) AU2013220139B2 (en)
BR (1) BR112014020008B1 (en)
CA (1) CA2864031C (en)
CY (1) CY1123202T1 (en)
DK (1) DK2814469T3 (en)
ES (1) ES2792069T3 (en)
GB (2) GB201202433D0 (en)
HK (1) HK1203824A1 (en)
HR (1) HRP20200780T1 (en)
HU (1) HUE048904T2 (en)
IL (2) IL234061B (en)
IN (1) IN2014DN06808A (en)
LT (1) LT2814469T (en)
ME (1) ME03742B (en)
MX (1) MX361407B (en)
NZ (2) NZ627468A (en)
PL (1) PL2814469T3 (en)
PT (1) PT2814469T (en)
RS (1) RS60346B1 (en)
RU (1) RU2619869C2 (en)
SI (1) SI2814469T1 (en)
WO (1) WO2013121184A1 (en)
ZA (1) ZA201508728B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
WO2016196687A1 (en) * 2015-06-01 2016-12-08 Massachusetts Institute Of Technology System and method for neuroendocrine control
FR3057775B1 (en) * 2016-10-26 2018-11-02 Crossject PHARMACEUTICAL SOLUTION OF HYDROCORTISONE FOR INJECTION DEVICE
KR101982287B1 (en) * 2019-01-04 2019-05-24 (주)청아굿푸드 Sustained-release granules containing natural extract and preparation method of the same
EP4277607A1 (en) 2021-01-15 2023-11-22 Galventa AG Pulsatile release caffeine formulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013711A (en) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− Penetrative local medicine composition containing corticosteroid
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
KR19990077278A (en) 1996-01-16 1999-10-25 마이클 오코넬 Local delivery of the drug to the lower gastrointestinal tract
DE19718012C1 (en) 1997-04-29 1998-10-08 Jenapharm Gmbh Process for the production of orally applicable solid pharmaceutical forms with controlled release of active substances
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
EP1315481B1 (en) * 2000-08-29 2006-12-06 Mepha AG Medicament for treating intestinal diseases
JP2004529902A (en) * 2001-03-13 2004-09-30 ペンウェスト ファーマシューティカルズ カンパニー Chronotherapeutic dosage forms containing glucocorticosteroids
DE20220917U1 (en) 2001-08-06 2004-08-19 Euro-Celtique S.A. Anti-abuse compositions for opioids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
DE60133319T3 (en) 2001-11-23 2021-08-05 Allergan pharmaceuticals International Ltd. MULTI-COATED PHARMACEUTICAL DOSAGE FORM
CA2538202C (en) 2003-09-15 2013-01-15 Altana Pharma Ag Use of ciclesonide for the treatment of inflammatory bowel diseases
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (en) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
MX2009001248A (en) * 2006-08-03 2009-02-11 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease.
BRPI0719319A2 (en) 2006-11-17 2014-02-04 Da Volterra COLONIC RELEASE USING ZN / PECTIN ACCOUNTS WITH AN EUDRAGIT COATING
US20100209520A1 (en) 2007-03-26 2010-08-19 Hiroyuki Kubo Oral pharmaceutical preparation for colon-specific delivery
JP2011506607A (en) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド Therapies for the treatment of immunoinflammatory disorders
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010113177A2 (en) 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
CA2757858C (en) * 2009-04-07 2017-03-28 Duocort Pharma Ab Improved glucocorticoid therapy
JP5907881B2 (en) 2009-11-16 2016-04-26 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ Method for converting solid (meth) acrylate copolymer into dispersed form with dispersant
IT1405012B1 (en) 2010-08-06 2013-12-16 Sofar Spa COMPOSITIONS OF BECLOMETASONE DIPROPIONIONATO IN GASTRORESISTANT MICROSPHERES WITH MODIFIED RELEASE AND PROCESS FOR THEIR OBJECTION
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release

Also Published As

Publication number Publication date
EP2814469B1 (en) 2020-04-08
GB2502402A (en) 2013-11-27
SI2814469T1 (en) 2020-07-31
NZ715616A (en) 2017-03-31
HK1203824A1 (en) 2015-11-06
US9750704B2 (en) 2017-09-05
CN104105481A (en) 2014-10-15
US20140370113A1 (en) 2014-12-18
IL234061A0 (en) 2014-09-30
GB2502402B (en) 2014-11-12
DK2814469T3 (en) 2020-05-04
RU2014130866A (en) 2016-04-10
CA2864031C (en) 2019-11-12
CY1123202T1 (en) 2021-10-29
BR112014020008B1 (en) 2022-05-24
JP2015506972A (en) 2015-03-05
HRP20200780T1 (en) 2020-10-02
JP6293678B2 (en) 2018-03-14
MX2014009716A (en) 2015-01-14
KR102023559B1 (en) 2019-09-23
PT2814469T (en) 2020-05-22
GB201302406D0 (en) 2013-03-27
RS60346B1 (en) 2020-07-31
MX361407B (en) 2018-12-04
KR20140121478A (en) 2014-10-15
ES2792069T3 (en) 2020-11-06
NZ627468A (en) 2016-02-26
AU2013220139A1 (en) 2014-08-07
HUE048904T2 (en) 2020-08-28
IL245546A0 (en) 2016-06-30
GB201202433D0 (en) 2012-03-28
CA2864031A1 (en) 2013-08-22
US20170296475A1 (en) 2017-10-19
BR112014020008A8 (en) 2018-01-23
ZA201508728B (en) 2017-09-27
ME03742B (en) 2021-04-20
AU2013220139B2 (en) 2017-08-31
RU2619869C2 (en) 2017-05-18
IL234061B (en) 2018-03-29
WO2013121184A1 (en) 2013-08-22
PL2814469T3 (en) 2020-07-13
CN110141557A (en) 2019-08-20
US10166194B2 (en) 2019-01-01
LT2814469T (en) 2020-05-25
EP2814469A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
EP2847152A4 (en) Compositions and methods for the treatment of metabolic syndrome
EP2815769A4 (en) Pharmaceutical use of fam19a5 involved in regulating gliogenesis
EP2885326A4 (en) Highly branched compositions and processes for the production thereof
PL2668182T3 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PL2668183T3 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
HRP20180633T1 (en) Methods for the preparation and delivery of fuel compositions
CY1123202T1 (en) CONTROLLED RELEASE HYDROCORTISONE FORMULATION
IN2013MU03641A (en)
IL243995A0 (en) Continuous release compositions made from hyaluronic acid, and therapeutic applications of same
EP2983789A4 (en) Compositions and methods for the delivery of therapeutics
HK1213891A1 (en) Process for the preparation of voriconazole and analogues thereof
PL2871941T3 (en) Compositions and methods for reducing the reproductive capacity of female rats
IL244537A0 (en) Novel delivery compositions and methods of using same
GB2527233A (en) Composition comprising hydrocortisone
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome
HK1207293A1 (en) Composition for the treatment of inflammatory and immune disorders
MY168958A (en) Intermediates and processes for preparing compounds
AU2013902392A0 (en) Delivery of Fuel in Full Load Operation
ZA201306087B (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation